RxDoctor Payments Data

David Monroe

Optometrist · Tarentum, PANPI 1194710749

Payments from drug & device makers

$5,276in general payments, 2019–2025

Across 160 payments — averaging $32.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$1K
  • Tarsus Pharmaceuticals, Inc.$1K
  • Johnson & Johnson Vision Care, Inc.$636
  • Oyster Point Pharma, Inc.$521
  • Alcon$450
  • Sun Pharmaceutical Industries Inc.$282
  • plus $811 from 11 others

What the payments were for

  • Food & beverage$5,24199%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,276 in reported general payments places this provider in the 90th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$20,576
Medicare patients
113
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast57$45,272
RestasisCyclosporine25$22,080
LumiganBimatoprost49$20,619
Cyclosporine54$20,433
XdemvyLotilaner11$19,806
VyzultaLatanoprostene Bunod31$7,493
Latanoprost126$1,998
Brimonidine Tartrate14$1,425
Fluorometholone22$1,416
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha41$397
Doxycycline Hyclate14$178
Timolol Maleate13$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$1,448$52,76588 claims
AbbVieRestasis, Lumigan$162$42,69974 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$1,129$19,80611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Tarentum

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →